FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)													
Name and Address of Reporting Person * Mann Brenda				2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X Officer (give title below) VP of Research & Development					
(Last) (First) (Middle) C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLY OAKS ROAD, SUITE 108				3. Date of Earliest Transaction (Month/Day/Year) 09/02/2021							VP of Re	esearch & De	evelopment		
(Street) WALTHAM, MA 02452				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui						ired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year	f Code (Instr. 8)		(A) or Dis (Instr. 3, 4		Disposed	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		ollowing	\ /	Beneficial Ownership	
					Со	ode	V	Amour	(A) or (D)	Price				or Indirect (I) (Instr. 4)	(Instr. 4)
Common Stock 09/02/2021			F	(1)		61	D	\$ 1.81	15,260			D			
Reminder:	Report on a s	separate line fo	r each class of secur				Pers cont the f	ons wl ained i orm di	no respo n this fo splays a	rm are curre	e not requ ntly valid	OMB conf	ormation spond unle trol numbe	SS	1474 (9-02)
				Derivative Securit e.g., puts, calls, wa							ny Owned				
Security	2. Conversion or Exercise Price of Derivative Security		Execution Da Year) any	te, if Transaction Code (Instr. 8)	Cransaction Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		Am Und Sec	ount of derlying purities str. 3 and Derivati		f 9. Number of e Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form o Derivat Security Direct (or Indir	Beneficia Ownersh (Instr. 4)	
				Code V	(A)	(D)	Date Exer	cisable	Expiratio Date	n Titl	Amount or Number of Shares				

Reporting Owners

	Relationships						
Reporting Owner Name / Address		10% Owner	Officer	Other			
Mann Brenda C/O EYEGATE PHARMACEUTICALS, INC. 271 WAVERLY OAKS ROAD, SUITE 108 WALTHAM, MA 02452			VP of Research & Development				

Signatures

/s/ Sarah Romano, Attorney-in-Fact*	09/03/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sale of shares to cover taxes due on restricted stock that vested on 09/01/2021.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.